J Dermatolog Treat. 2023 Feb 21:1-3. doi: 10.1080/09546634.2023.2182619. Online ahead of print.
ABSTRACT
Lenalidomide is a relatively new targeted immunomodulatory drug, used for the treatment of multiple mieloma. We reported a case of a 54-year-old man with multiple mieloma, who developed psoriasis exacerbation concomitantly with lenalidomide treatment. We proposed to avoid discontinuation of the life-sparing agent and started topical treatment and phototherapy, finally achieving PASI 90. The mechanism by which these reactions occur is not fully understood, although an interaction between TNF-α and interferon alfa (IFN-α) has been suggested. To the best of our knowledge, this is the first reported case of psoriasis exacerbation by lenalidomide.
PMID:36809149 | DOI:10.1080/09546634.2023.2182619